The Alzheimer’s Drug Discovery Foundation (ADDF) announced today that it has awarded $1 million to GliaCure, a biotechnology company developing innovative therapies based on glial targets, to co-fund a Phase 1b clinical trial in patients with mild to moderate Alzheimer’s disease. The study, which recently began screening volunteers, will determine the safety and tolerability of GliaCure’s primary clinical candidate, GC021109. It follows a 2014 Phase 1a trial which showed GC021109 to be safe and well tolerated in healthy volunteers.
The Alzheimer’s Drug Discovery Foundation (ADDF) is pleased to announce that it is an Official Charity Partner of the 2015 TCS New York City Marathon. The ADDF invites runners who did not secure an individual spot in the 2015 TCS New York City Marathon to join its Runners for Alzheimer’s Research team on Sunday, November 1, 2015.
The Alzheimer’s Drug Discovery Foundation (ADDF) and Pfizer’s Centers for Therapeutic Innovation (CTI) announced today a collaboration designed to advance the development of new small-molecule drugs for Alzheimer’s disease and related dementias. As part of the first-of-its kind collaboration in Alzheimer’s, the ADDF and CTI will jointly invest in translational research projects, with a focus on novel Alzheimer’s drug targets.
The Alzheimer’s Drug Discovery Foundation (ADDF) announced today a $900,000 grant to AgeneBio, a pharmaceutical company developing innovative therapies for neurologic and psychiatric diseases. The grant will support the initiation of an FDA-registered Phase 3 clinical trial of AGB101, a new therapeutic treatment for amnestic mild cognitive impairment (aMCI). aMCI is a condition in which memory is worse than to be expected for a person’s age and is considered the pre-dementia stage of Alzheimer’s disease. This is the second grant that the ADDF has made to AgeneBio.
The Alzheimer’s Drug Discovery Foundation (ADDF) and Axxam SpA (Axxam) announced today that ADDF has awarded a follow-on grant to Axxam to further develop small molecule drugs to treat Alzheimer’s disease by targeting inflammation. This grant follows two previous awards by ADDF to Axxam in 2011 and 2013. The award will continue to fund a drug discovery project to identify compounds that selectively block the purinergic receptor, P2X7, which is involved in inflammation in the brain. Research activities under the previous grants have identified a new class of promising P2X7 selective antagonists that are currently under full expansion as well as lead compounds suitable for in vivo assessment in pharmacological models.
Today, the Alzheimer’s Drug Discovery Foundation (ADDF) and the Alzheimer’s Society UK announced new funding to explore the possibility of using a commonly prescribed drug which treats erectile dysfunction as the next treatment for dementia. Tadalafil – part of the same class of drugs as Viagra – is to be one of the major research programs funded by the two charities in a cross-Atlantic research partnership. This is the first ever study researching the use of an erectile dysfunction drug for vascular dementia.
On Monday, former model and restaurateur B. Smith was honored by the Alzheimer’s Drug Discovery Foundation (ADDF) at its Fifth Annual Fall Symposium & Luncheon “Hope on the Horizon” at The Pierre in New York City. Smith, who publicly revealed her early-onset Alzheimer’s diagnosis in June, was presented with The Charles Evans Award at Monday’s Luncheon for using her powerful platform to promote public awareness and raise critical funds to combat Alzheimer’s disease. Smith graciously accepted the award in a purple dress, the official color of d National Alzheimer’s Disease Awareness Month, with her husband and long-time business partner Dan Gasby by her side.
The Alzheimer’s Drug Discovery Foundation (ADDF) and OnDeckBiotech announced today the launch of ADDF ACCESS, a new and improved open access platform to connect scientists with a virtual network of contract research organizations (CROs), drug development experts and educational resources. By leveraging OnDeckBiotech’s cutting-edge technology, the enhanced ADDF ACCESS platform will streamline links between researchers and CROs specializing in diseases of the central nervous system (CNS) to expedite drug discovery research and development. The announcement came on day three of the ADDF’s 15th International Conference on Alzheimer’s Drug Discovery.
A new peer-reviewed publication from the Alzheimer’s Drug Discovery Foundation (ADDF) and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) offers strategic insight on how philanthropy, industry and government organizations can advance repurposing of U.S. Food and Drug Administration (FDA)-approved drugs for the treatment of neurodegenerative diseases. The paper, published in the Annals of Clinical and Translational Neurology, was produced in collaboration with experts from these sectors and highlights the unique challenges and lack of commercial incentives for testing approved drugs in new disease indications, like Alzheimer’s or Parkinson’s disease, where they might be beneficial.
The Alzheimer’s Drug Discovery Foundation (ADDF) and OnDeckBiotech announced today a strategic partnership to provide a new platform technology for ADDF ACCESS. ADDF ACCESS is an open access database that provides a network of contract research organizations (CROs), drug development consultants and educational resources focused for diseases of the central nervous system (CNS). By leveraging OnDeckBiotech’s cutting-edge technology, ADDF ACCESS will increase the efficiency of contracting drug development services by scientists in academia and small biotechnology companies.